Solid forms of a compound modulating kinases
AssigneePlexxikon Inc.
InventorsPrabha N. Ibrahim, Gary Conard Visor
Life of this patent
Estimating the term…
Abstract
Solid forms of the compound, [5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine HCl salt (Compound I) and its free base, active on the receptor protein kinases c-Kit and/or c-Fms and/or Flt3, were prepared and characterized: Also provided are methods of using the solid forms.
Claims14
A crystalline form of Compound I:
- which is Compound I Form A, characterized by an X-ray powder diffractogram comprising peaks (±0.2°) at 7.1, 22.9 and 27.6 °2θ as determined on a diffractometer usino Cu—Kα radiation.
A crystalline form of Compound I:
- which is Compound I Form B, characterized by an X-ray powder diffractoaram comprising peaks (±0.2°) at 6.6, 23.2 and 28.1 °2θ as determined on a diffractometer using Cu—Kα radiation.
A crystalline form of Compound I:
- which is Compound I Form C, characterized by an X-ray powder diffractogram comprising peaks (±0.2°) at 7.3, 23.3 and 28.2 °2θ as determined on a diffractometer using Cu—Kα radiation.
A crystalline form of Compound I:
- which is Compound I Form D, wherein the crystalline form is a methanol solvate, characterized by an X-ray powder diffractogram comprising peaks (±0.2°) at 6.9, 20.9 and 26.7 °2θ as determined on a diffractometer using Cu—Kα radiation.
A crystalline form of Compound II:
- characterized by an X-ray powder diffractogram comprising peaks (±0.2°) at 10.9, 19.7 and 26.4 °2θ as determined on a diffractometer using Cu—Kα radiation.
A process of preparing a capsule comprising Compound I Form C comprising combining Compound I Form C with a pharmaceutically acceptable carrier or excipient.
A process of preparing a tablet comprising Compound I Form C comprising combining Compound I Form C with a pharmaceutically acceptable carrier or excipient.
Dependencies are inferred from the claim text.